Toll-Like Receptors (TLR Receptors)

📋 Key Information Summary

📋

Toll-like receptors (TLRs) are germline-encoded pattern recognition receptors (PRRs) that detect pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), forming the first line of innate immune defence.
Humans express 10 functional TLRs (TLR1–TLR10); TLR1, 2, 4, 5, 6, 10 are surface-localised; TLR3, 7, 8, 9 reside in endosomes and detect nucleic acids.
TLR4 recognises lipopolysaccharide (LPS) from Gram-negative bacteria — the most clinically studied TLR and central to sepsis pathophysiology in Australian ICUs.
TLR3 detects double-stranded RNA (dsRNA) and signals exclusively via TRIF, producing robust type I interferon (IFN-α/β) responses critical for antiviral immunity.
Two major signalling cascades: MyD88-dependent (all TLRs except TLR3) and TRIF/TICAM1-dependent (TLR3 and TLR4), converging on NF-κB, MAPK, and IRF transcription factors.
Downstream effects include pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6, IL-12), type I interferon production, dendritic cell maturation, and adaptive immune priming.
Loss-of-function polymorphisms (e.g., TLR4 Asp299Gly, TLR3 deficiency) predispose to severe Gram-negative infections, herpes simplex encephalitis, and impaired vaccine responses.
Gain-of-function or chronic TLR activation drives pathological inflammation in sepsis, atherosclerosis, inflammatory bowel disease, systemic lupus erythematosus, and rheumatoid arthritis.
TLR agonists are licensed therapeutics: imiquimod (TLR7, Aldara®) for superficial skin cancers; BCG (multiple TLRs) for bladder cancer; CpG oligonucleotides (TLR9) as vaccine adjuvants.
TLR-targeted biologics (eritoran — TLR4 antagonist) have not demonstrated mortality benefit in large sepsis trials; current Australian practice relies on source control and empirical antibiotics per eTG.
Aboriginal and Torres Strait Islander populations carry a higher burden of infections where TLR-mediated immunity is critical; genetic TLR polymorphism studies are ongoing.
Understanding TLR biology is essential for interpreting vaccine adjuvant mechanisms, primary immunodeficiency workup, and novel immunotherapy strategies in Australian clinical practice.

Introduction & Australian Epidemiological Context

Toll-like receptors (TLRs) are evolutionarily conserved type I transmembrane glycoproteins that function as sentinels of the innate immune system. First characterised through the Drosophila Toll protein in the 1990s and subsequently identified in humans by the laboratory of Bruce Beutler (Nobel Prize in Physiology or Medicine, 2011), TLRs recognise conserved microbial structures — pathogen-associated molecular patterns (PAMPs) — as well as endogenous danger signals released during cellular stress (damage-associated molecular patterns, DAMPs). Activation of TLRs triggers intracellular signalling cascades that culminate in the transcription of pro-inflammatory cytokines, chemokines, type I interferons, and co-stimulatory molecules, thereby shaping both innate and adaptive immune responses.

In Australia, TLR-mediated immunity is clinically relevant across a broad spectrum of infectious and inflammatory conditions. Sepsis accounts for approximately 18 000 hospital separations annually (Australian Institute of Health and Welfare, 2023), with TLR4-mediated recognition of Gram-negative lipopolysaccharide central to the initial cytokine storm. Recurrent herpes simplex encephalitis, a condition linked to TLR3 deficiency, is diagnosed at major tertiary centres including the Royal Children's Hospital Melbourne and Westmead Hospital Sydney. Furthermore, TLR-based therapies — including imiquimod cream (Aldara®) for superficial basal cell carcinoma and BCG intravesical therapy for non-muscle-invasive bladder cancer — are listed on the Pharmaceutical Benefits Scheme (PBS) and prescribed widely across Australian primary care and specialist settings.

This guideline provides a comprehensive overview of TLR types and their ligands, intracellular signalling pathways, downstream immunological effects, and clinical significance relevant to Australian healthcare practitioners, including considerations for Aboriginal and Torres Strait Islander populations and primary immunodeficiency evaluation.

TLR Types & Ligands

Humans express 10 functional Toll-like receptors (TLR1–TLR10). Each TLR recognises specific molecular patterns derived from bacteria, viruses, fungi, or parasites. TLRs are classified by cellular localisation: surface TLRs detect microbial membrane components, while endosomal TLRs detect nucleic acids following phagocytic uptake.

TLR	Localisation	Primary Ligand (PAMP)	Microbial Source	Key Function
TLR1	Cell surface	Triacyl lipopeptides (with TLR2)	Bacteria, mycobacteria	Heterodimerises with TLR2; senses bacterial lipoproteins
TLR2	Cell surface	Lipoteichoic acid, peptidoglycan, lipoproteins, zymosan	Gram-positive bacteria, fungi, mycobacteria	Broad-spectrum microbial sensor; forms heterodimers with TLR1 or TLR6
TLR3	Endosome	Double-stranded RNA (dsRNA)	Viruses (e.g., influenza, HSV, West Nile)	Antiviral IFN-α/β production via TRIF
TLR4	Cell surface	Lipopolysaccharide (LPS)	Gram-negative bacteria	Central to sepsis; uses both MyD88 and TRIF pathways; requires MD-2 and CD14 co-receptors
TLR5	Cell surface	Flagellin	Flagellated bacteria (e.g., Salmonella, Pseudomonas)	Mucosal defence in gut and respiratory tract
TLR6	Cell surface	Diacyl lipopeptides (with TLR2)	Mycoplasma, Gram-positive bacteria	Heterodimerises with TLR2; senses mycoplasmal lipoproteins
TLR7	Endosome	Single-stranded RNA (ssRNA)	Viruses (e.g., influenza, HIV, SARS-CoV-2)	Antiviral immunity; therapeutic target (imiquimod)
TLR8	Endosome	Single-stranded RNA (ssRNA)	Viruses, bacteria	Strong TNF-α and IL-12 induction; important in human monocyte activation
TLR9	Endosome	Unmethylated CpG DNA	Bacteria, DNA viruses (HSV, CMV)	IFN-α production; vaccine adjuvant target (CpG ODN)
TLR10	Cell surface	Uncertain (may sense dsRNA or lipopeptides)	Unknown; possibly viral	May function as anti-inflammatory receptor; least characterised

⚠️

Clinical pearl: TLR4 is the only TLR that signals via both MyD88-dependent and TRIF-dependent pathways. This dual signalling enables sustained NF-κB activation and type I interferon production, making TLR4 a particularly potent driver of the inflammatory cascade during Gram-negative sepsis.

Endogenous Ligands (DAMPs)

In addition to microbial PAMPs, TLRs recognise endogenous danger signals released during tissue injury, sterile inflammation, and necrotic cell death. These DAMPs include heat shock proteins (HSP60, HSP70), high-mobility group box 1 (HMGB1), fibronectin extra-domain A, hyaluronan fragments, and self-DNA/RNA complexes. Chronic DAMP-driven TLR activation is implicated in atherosclerosis, rheumatoid arthritis, systemic lupus erythematosus, and ischaemia–reperfusion injury — all conditions encountered in Australian clinical practice.

Signalling Pathways

TLR signalling proceeds through two major intracellular pathways: the MyD88-dependent pathway and the TRIF (TICAM1)-dependent pathway. The choice of pathway depends on the TLR involved and determines the transcriptional outcome — predominantly NF-κB-mediated pro-inflammatory cytokine production versus IRF-mediated type I interferon responses.

MyD88-Dependent Pathway

The adaptor protein myeloid differentiation primary response 88 (MyD88) is utilised by all TLRs except TLR3. Upon ligand binding, TLRs recruit MyD88 via homotypic Toll/interleukin-1 receptor (TIR) domain interactions. MyD88 then recruits IL-1 receptor-associated kinases (IRAK4, IRAK1, IRAK2), forming the "Myddosome" complex. IRAK4 phosphorylates IRAK1, which then associates with TNF receptor-associated factor 6 (TRAF6). TRAF6, together with the E2 ubiquitin-conjugating enzyme complex Ubc13/Uev1A, generates K63-linked polyubiquitin chains that activate the TAK1 (TGF-β-activated kinase 1) complex.

TAK1 activates two downstream branches:

NF-κB pathway: TAK1 phosphorylates the IKK complex (IKKα/IKKβ/NEMO), which degrades IκBα, releasing NF-κB (p50/p65) to translocate to the nucleus and drive transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-12p40) and co-stimulatory molecules (CD80, CD86).
MAPK pathway: TAK1 also activates MAP kinase cascades (ERK1/2, JNK, p38), leading to activation of AP-1 transcription factors that synergise with NF-κB for maximal cytokine gene expression.

TRIF-Dependent Pathway

The adaptor TIR-domain-containing adaptor-inducing IFN-β (TRIF, also known as TICAM1) mediates signalling from TLR3 exclusively and from TLR4 in its second (late) signalling phase following endocytosis. TRIF recruits TRAF3, which activates the kinases TBK1 (TANK-binding kinase 1) and IKKε. These kinases phosphorylate interferon regulatory factor 3 (IRF3) and IRF7, promoting their dimerisation, nuclear translocation, and transcription of type I interferons (IFN-α, IFN-β) and interferon-stimulated genes (ISGs).

TRIF also engages TRAF6 and the kinase RIP1 (receptor-interacting protein 1), activating a late-phase NF-κB response independent of MyD88. This dual signalling capacity of TLR4 — early MyD88-dependent and late TRIF-dependent — explains its uniquely broad transcriptional output.

Negative Regulation

Excessive TLR signalling is controlled by multiple negative regulators to prevent immunopathology:

SIGIRR (TIR8): Decoy TIR-domain receptor that inhibits TLR4 and TLR7/9 signalling in intestinal epithelium.
A20 (TNFAIP3): Deubiquitinase that removes K63-linked ubiquitin chains from TRAF6 and RIP1, terminating NF-κB signalling.
SOCS1: Targets MAL/TIRAP for proteasomal degradation, attenuating MyD88-dependent signalling.
IRAK-M: Inactive IRAK family member that prevents dissociation of IRAK1 from the MyD88 complex.
MicroRNAs: miR-146a/b downregulates IRAK1 and TRAF6 expression; miR-155 modulates TAB2.

ℹ️

For immunology trainees: The MyD88 pathway is the primary driver of NF-κB-mediated cytokine production (TNF-α, IL-6), while the TRIF pathway is essential for IRF-mediated type I interferon (IFN-α/β) production. TLR4 uniquely engages both pathways sequentially — MyD88 at the plasma membrane, TRIF following endosomal internalisation.

Downstream Effects

TLR activation triggers a coordinated programme of innate and adaptive immune responses. The downstream effects vary by TLR, cell type, and signalling pathway engaged, but collectively serve to eliminate pathogens, recruit immune cells, and initiate adaptive immunity.

Pro-Inflammatory Cytokine & Chemokine Production

NF-κB activation drives transcription of key pro-inflammatory mediators:

Mediator	Primary Source	Key Functions	Clinical Relevance
TNF-α	Macrophages, monocytes	Fever, acute-phase response, endothelial activation, apoptosis	Central mediator of septic shock; target of anti-TNF biologics in RA
IL-1β	Macrophages, dendritic cells	Fever, neutrophil recruitment, Th17 polarisation	Requires NLRP3 inflammasome cleavage; target of anakinra (Kineret®)
IL-6	Macrophages, endothelium	Acute-phase protein induction (CRP, fibrinogen), B-cell differentiation	Elevated in sepsis, RA, Castleman disease; target of tocilizumab
IL-12	Dendritic cells, macrophages	Th1 polarisation, IFN-γ induction in NK and T cells	Critical for intracellular pathogen defence (mycobacteria, Leishmania)
IL-10	Macrophages, Tregs	Anti-inflammatory; limits tissue damage	Regulatory counterbalance; deficiency causes inflammatory bowel disease
CXCL8 (IL-8)	Macrophages, epithelium	Neutrophil chemotaxis	Rapid neutrophil recruitment to sites of bacterial infection

Type I Interferon Production

TLR3, TLR7, TLR8, and TLR9 (endosomal nucleic acid-sensing TLRs) activate IRF3/IRF7 via TRIF or MyD88, driving transcription of IFN-α (13 subtypes) and IFN-β. Type I interferons induce an antiviral state in neighbouring cells by upregulating hundreds of interferon-stimulated genes (ISGs) including Mx proteins, OAS/RNase L, PKR, IFITM proteins, and APOBEC3G. This response is critical for containment of viral infections including influenza, SARS-CoV-2, and herpes simplex virus.

Dendritic Cell Maturation & Adaptive Immune Priming

TLR activation in dendritic cells (DCs) triggers a maturation programme essential for bridging innate and adaptive immunity:

Upregulation of MHC class II: Enhanced antigen presentation to CD4+ T cells.
Expression of co-stimulatory molecules: CD80 (B7-1), CD86 (B7-2), and CD40 provide Signal 2 for T-cell activation, preventing anergy.
Cytokine-directed T-cell polarisation: IL-12 drives Th1; IL-6 + TGF-β drives Th17; IFN-α enhances cytotoxic T lymphocyte (CTL) responses.
Lymph node migration: Upregulation of CCR7 directs DCs to T-cell zones of draining lymph nodes.

Inflammasome Cross-Talk

TLR signalling provides "Signal 1" (priming) for NLRP3 inflammasome activation by upregulating pro-IL-1β and NLRP3 expression. A second signal (e.g., ATP, crystalline urate, bacterial toxins) then triggers inflammasome assembly, caspase-1 activation, and mature IL-1β/IL-18 secretion. This two-step model is clinically relevant in gout, pseudogout, and silicosis — conditions managed by Australian rheumatologists.

Clinical Significance

TLR biology has direct relevance to multiple areas of Australian clinical medicine, including infectious diseases, immunodeficiency, rheumatology, oncology, and vaccinology.

Sepsis & TLR4

TLR4-mediated recognition of LPS is the initiating event in Gram-negative sepsis. Activation triggers massive TNF-α, IL-1β, and IL-6 release, leading to vasodilation, capillary leak, disseminated intravascular coagulation (DIC), and multi-organ failure. TLR4 also senses DAMPs (HMGB1, HSPs) during later phases, perpetuating inflammation even after pathogen clearance. TLR4 antagonists (eritoran, TAK-242) showed promise in preclinical models but failed to demonstrate mortality benefit in large randomised controlled trials (ACCESS trial, 2013). Current Australian management of sepsis prioritises source control, empirical antibiotics, and haemodynamic resuscitation per the Surviving Sepsis Campaign guidelines, adopted in Australian ICUs.

🚨

Sepsis warning: Delayed recognition of sepsis carries a mortality rate exceeding 40% in Australia. TLR4-driven cytokine release occurs within minutes of LPS exposure. The first hour of management ("the golden hour") should include IV antibiotics, fluid resuscitation, and lactate measurement as per the Australian Commission on Safety and Quality in Health Care (ACSQHC) Sepsis Clinical Care Standard (2022).

Primary Immunodeficiency & TLR Defects

Genetic defects in TLR signalling components cause specific primary immunodeficiency syndromes:

Defect	Gene	TLR Affected	Clinical Phenotype	Australian Relevance
MyD88 deficiency	MYD88	All except TLR3	Recurrent pyogenic bacterial infections (S. pneumoniae, S. aureus) in childhood	Diagnosed at paediatric immunology centres (RCH Melbourne, Sydney Children's)
IRAK-4 deficiency	IRAK4	All except TLR3	Invasive pneumococcal disease, other pyogenic infections; improves with age	Included in expanded newborn screening discussions
TLR3 deficiency	TLR3	TLR3	Herpes simplex encephalitis (HSE) in otherwise healthy children/adults	Consider in recurrent or atypical HSE presentations
UNC93B1 deficiency	UNC93B1	TLR3, 7, 8, 9	Herpes simplex encephalitis	Functional TLR3 assay available at reference laboratories

TLR-Based Therapeutics

Several TLR-targeted agents are available in Australia:

💊

Imiquimod

Aldara® · TLR7 agonist

Adult dose 5% cream applied 3×/week for 6 weeks (superficial BCC); 5×/week for 4 weeks (actinic keratosis)

Mechanism TLR7 activation → local IFN-α, TNF-α, IL-12 production → enhanced cytotoxic T-cell and NK-cell activity against tumour cells

PBS status ✔ PBS General Benefit

💊

BCG (Bacillus Calmette-Guérin)

OncoTICE® · Multiple TLR agonist (TLR2/4)

Adult dose Intravesical instillation 81 mg (1 vial) weekly × 6 weeks induction, then maintenance per protocol

Mechanism TLR2/4 activation on urothelial immune cells → Th1 cytokine cascade → anti-tumour immunity

PBS status ✔ PBS General Benefit

💊

AS04 (MPL adjuvant)

Component of Cervarix® (HPV vaccine) · TLR4 agonist

Dose 0.5 mL IM; schedule per NIP (2-dose if <15 years, 3-dose if ≥15 years)

Mechanism Monophosphoryl lipid A (MPL) activates TLR4 → enhanced antigen presentation and antibody responses to HPV VLPs

PBS status ✔ NIP (National Immunisation Programme) — free for eligible cohorts

Autoimmune & Inflammatory Disease

Chronic or inappropriate TLR activation contributes to the pathogenesis of several autoimmune conditions managed in Australian specialist practice:

Systemic lupus erythematosus (SLE): Immune complexes containing self-DNA and self-RNA activate TLR9 and TLR7, respectively, in plasmacytoid dendritic cells, driving IFN-α overproduction — the "interferon signature" characteristic of SLE. Hydroxychloroquine, a mainstay of SLE therapy in Australia, inhibits endosomal TLR activation by raising endosomal pH.
Rheumatoid arthritis (RA): TLR2 and TLR4 are upregulated on synovial macrophages; their activation by DAMPs (fibronectin fragments, HSPs, HMGB1) sustains synovial inflammation and joint destruction.
Inflammatory bowel disease (IBD): TLR signalling in intestinal epithelial cells maintains barrier integrity; dysregulated TLR2/4 responses contribute to Crohn's disease pathogenesis. SIGIRR (TIR8) polymorphisms are associated with IBD susceptibility.
Atherosclerosis: TLR2 and TLR4 on macrophages recognise oxidised LDL and DAMPs within atherosclerotic plaques, promoting foam cell formation and plaque instability.

Vaccine Adjuvants

TLR agonists are increasingly used as vaccine adjuvants to enhance immunogenicity:

AS01 (shingles vaccine — Shingrix®): Contains MPL (TLR4 agonist) plus QS-21 saponin; achieves >90% efficacy against herpes zoster even in immunocompromised patients. Available on NIP for adults ≥65 years and immunocompromised patients ≥18 years in Australia.
AS04 (HPV vaccine — Cervarix®): MPL adsorbed to aluminium salt (TLR4 agonist); induces stronger and more durable antibody responses than aluminium alone.
CpG 1018 (Heplisav-B®): TLR9 agonist adjuvant for hepatitis B vaccine; 2-dose schedule with higher seroprotection rates. Not yet PBS-listed in Australia but available privately.

TLR Polymorphisms & Susceptibility

Common single nucleotide polymorphisms (SNPs) in TLR genes modulate infection susceptibility and disease severity:

Polymorphism	Gene	Effect	Clinical Association
Asp299Gly	TLR4	Reduced LPS responsiveness	Increased Gram-negative infection risk; reduced atherosclerosis
Thr399Ile	TLR4	Reduced LPS responsiveness	Haplotype-dependent; associated with malaria resistance
Arg753Gln	TLR2	Impaired lipopeptide recognition	Increased susceptibility to tuberculosis, leprosy
P554S	TLR3	Loss of function	Herpes simplex encephalitis in children
−1237C	TLR9	Increased transcriptional activity	Associated with SLE susceptibility in some populations

Pathophysiology

The pathophysiological role of TLRs extends from protective antimicrobial immunity to pathological inflammation in autoimmunity, chronic infection, and malignancy. Understanding the balance between protective TLR activation and harmful dysregulation is central to clinical application.

Protective Immunity

Under normal physiological conditions, TLR activation provides rapid, localised antimicrobial defence:

Epithelial barrier defence: TLR2, TLR4, and TLR5 on mucosal epithelial cells (gut, respiratory tract, urinary tract) detect commensal-derived and pathogenic signals, maintaining barrier homeostasis through antimicrobial peptide (defensin, cathelicidin) production and tight junction regulation.
Phagocyte activation: Macrophages and neutrophils upregulate reactive oxygen species (ROS) production, phagolysosomal killing, and neutrophil extracellular trap (NET) formation following TLR engagement.
Antiviral state: Endosomal TLR3/7/8/9-mediated IFN-α/β production induces an antiviral state in uninfected cells, limiting viral spread.

Pathological Hyperactivation — Sepsis Paradigm

Excessive TLR signalling during overwhelming infection leads to the systemic inflammatory response syndrome (SIRS) characteristic of sepsis:

Massive TNF-α and IL-1β release causes systemic vasodilation, capillary leak, and hypotension.
IL-6 drives hepatic acute-phase response (CRP, ferritin, fibrinogen) and contributes to DIC via tissue factor upregulation.
Endothelial activation and coagulation cascade activation lead to microvascular thrombosis and organ ischaemia.
Late-phase DAMP signalling (HMGB1 → TLR4) perpetuates inflammation even after successful antimicrobial therapy, contributing to immunoparalysis.

Sterile Inflammation & Autoimmunity

In the absence of infection, TLR activation by endogenous DAMPs drives pathological sterile inflammation:

SLE: Self-nucleic acids in immune complexes activate TLR7 (ssRNA) and TLR9 (DNA) on plasmacytoid DCs, producing pathological IFN-α. This drives B-cell activation, autoantibody production (anti-dsDNA, anti-Smith), and immune complex deposition.
Gout: Monosodium urate (MSU) crystals provide Signal 2 for NLRP3 inflammasome activation following TLR priming (Signal 1) by gut-derived LPS or endogenous DAMPs.
Atherosclerosis: Oxidised phospholipids and HMGB1 in atherosclerotic plaques activate TLR2/4 on macrophages, perpetuating inflammation and promoting plaque rupture.

Tumour Immune Evasion

Tumours exploit TLR signalling for immune evasion and growth promotion. Tumour-derived exosomes carrying HSP70 and HMGB1 activate TLR2/4 on myeloid-derived suppressor cells (MDSCs), promoting immunosuppressive microenvironments. Conversely, therapeutic TLR activation (imiquimod, BCG) can overcome immune evasion by restoring anti-tumour immunity.

Investigations

TLR pathway assessment is primarily indicated in the evaluation of primary immunodeficiency, recurrent or atypical infections, and research settings. Clinical TLR functional testing is available through specialised immunology laboratories in Australia.

Specialist TLR functional assay (whole blood or PBMC stimulation) Stimulate patient cells with specific TLR ligands (LPS for TLR4, poly(I:C) for TLR3, CpG for TLR9) and measure cytokine production (TNF-α, IL-6, IFN-α) by ELISA or flow cytometry. Available at: Royal Children's Hospital Melbourne, Westmead Hospital Sydney immunology laboratories. MBS item: specialist request only.

Specialist Targeted gene sequencing (MYD88, IRAK4, TLR3, UNC93B1, TIRAP) Indicated for suspected primary immunodeficiency with recurrent pyogenic infections or herpes simplex encephalitis. Available through clinical genetics services and research laboratories (e.g., Murdoch Children's Research Institute). MBS item: MBS 73295 (targeted sequencing) or via genomic Medicare if criteria met.

Available Whole exome/genome sequencing (WES/WGS) For undiagnosed primary immunodeficiency with negative targeted testing. Available through Australian Genomics Health Alliance and state-based genomic medicine services. Increasingly funded under Medicare for suspected inborn errors of immunity.

Available Flow cytometry — TLR surface expression and downstream signalling Phospho-flow cytometry for NF-κB (p65), IRF3, and MAPK phosphorylation following TLR stimulation. Research-grade assay; available at major academic centres.

Available Inflammatory markers (CRP, procalcitonin, IL-6, ferritin) Surrogate markers of TLR-driven cytokine activation in sepsis and inflammatory conditions. CRP: MBS item 65070; Procalcitonin: available at major hospitals (special request). Not specific to TLR activation but reflect downstream NF-κB pathway activity.

Available Type I interferon signature (gene expression panel) Quantitative PCR or NanoString panel measuring ISG expression (IFIT1, MX1, ISG15, OAS1). Available at research laboratories (Garvan Institute, WEHI). Clinically used in SLE assessment and interferonopathies.

ℹ️

When to consider TLR pathway testing: Suspect TLR signalling defects in patients with recurrent invasive pyogenic infections (especially S. pneumoniae) from early childhood, herpes simplex encephalitis in immunocompetent hosts, or unexplained susceptibility to specific pathogen classes. Consult a clinical immunologist prior to testing.

Monitoring

Monitoring in TLR-related conditions focuses on disease activity in autoimmune conditions driven by chronic TLR activation, response to TLR-based therapeutics, and immunodeficiency surveillance.

Condition	Monitoring Parameters	Frequency
SLE (TLR7/9-driven IFN-α)	Anti-dsDNA titre, complement (C3/C4), urinalysis, CRP/ESR, SLEDAI-2K score, IFN-α gene signature	Every 1–3 months if active; 6-monthly if stable
Sepsis (TLR4-mediated)	Lactate, CRP, procalcitonin, organ function (creatinine, bilirubin, platelets), SOFA score	Continuous haemodynamic; labs every 6–12 hours in ICU
Imiquimod therapy (TLR7 agonist)	Local skin reaction (erythema, erosion), treatment response (clinical ± dermoscopy), systemic side effects (flu-like symptoms)	4-weekly during treatment; post-treatment review at 3 months
BCG intravesical (TLR2/4 agonist)	Cystoscopy with biopsies, urine cytology, adverse events (cystitis, haematuria, BCG sepsis)	3-monthly cystoscopy for 2 years, then 6-monthly to 5 years
Primary immunodeficiency (MyD88/IRAK-4)	Infection frequency, immunoglobulin levels (IgG, IgA, IgM), vaccine responses (pneumococcal serology), growth and development	3–6-monthly with clinical immunologist

Special Populations

👶 Paediatrics

MyD88/IRAK-4 deficiency Presents in infancy with recurrent severe pyogenic infections (meningitis, septicaemia, deep-seated abscesses) caused by Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa. Severity decreases with age as adaptive immunity matures. Lifelong antibiotic prophylaxis (phenoxymethylpenicillin 250–500 mg BD PO) and rapid access to IV antibiotics are essential.

TLR3 deficiency Major risk factor for herpes simplex encephalitis (HSE) in otherwise healthy children. Consider TLR3 pathway testing in any child with HSE, particularly if recurrent or affecting an unusual brain region (e.g., brainstem). Acyclovir remains first-line treatment.

Vaccine responses TLR-mediated DC maturation is critical for effective vaccine responses. Children with TLR signalling defects may have impaired responses to conjugate vaccines. Check post-vaccination serology for S. pneumoniae and Haemophilus influenzae type b.

🤰 Pregnancy

Imiquimod 5% cream Category B3. Not recommended during pregnancy; systemic absorption possible though minimal. Defer treatment to post-partum unless clinical urgency. Barrier contraception advised during treatment.

TLR-mediated placental immunity TLRs are expressed on trophoblasts and decidual immune cells; their activation is essential for defence against ascending genital tract infections but excessive activation is associated with preterm labour and pre-eclampsia. TLR4-mediated LPS recognition in the placenta may contribute to infection-associated preterm birth.

👴 Elderly

TLR function & immunosenescence Ageing is associated with dysregulated TLR expression and function: increased basal TLR4 activation (contributing to chronic low-grade inflammation or "inflammageing") but impaired TLR-induced cytokine responses to novel pathogens. This contributes to increased susceptibility to influenza, pneumococcal disease, and poor vaccine responses in older Australians. Shingrix® (AS01 adjuvant containing TLR4 agonist MPL) achieves >90% efficacy in adults ≥70 years partly by overcoming this adjuvant-dependent defect.

🫘 Renal Impairment

TLR & uraemia Chronic kidney disease is associated with impaired TLR2 and TLR4 function on monocytes, contributing to the immunodeficiency of uraemia. Patients on haemodialysis are exposed to LPS from dialysate water, causing chronic TLR4 activation and contributing to chronic inflammation, accelerated atherosclerosis, and erythropoietin resistance. LPS-free dialysate is standard in Australian dialysis units per ANZDATA guidelines.

🫁 Hepatic Impairment

TLR & liver disease Kupffer cells (liver-resident macrophages) express TLR2, TLR4, and TLR9. In cirrhosis, impaired hepatic LPS clearance leads to chronic TLR4 activation, contributing to portal hypertension, hepatic encephalopathy, and increased susceptibility to spontaneous bacterial peritonitis (SBP). Norfloxacin prophylaxis (400 mg daily PO) reduces SBP risk partly by reducing gut bacterial translocation and TLR4 ligand load. TLR3-mediated antiviral responses are important in hepatitis B and C clearance.

🛡️ Immunocompromised

HIV/AIDS HIV infection upregulates TLR7/8 expression on plasmacytoid DCs but impairs downstream signalling, contributing to chronic immune activation and immunodeficiency. TLR7 polymorphisms may influence HIV disease progression. ART partially restores TLR function.

Transplant recipients TLR activation on donor or recipient immune cells contributes to allograft rejection. TLR2 and TLR4 polymorphisms in kidney transplant donors/recipients influence acute rejection risk. TLR3-mediated innate antiviral responses are critical for CMV and BK virus defence post-transplant.

Biologic therapy Anti-TNF agents (adalimumab, infliximab) reduce TLR-driven TNF-α but increase infection risk, particularly reactivation of latent tuberculosis (TLR2-mediated containment). Baseline IGRA/QFT testing is mandatory before anti-TNF therapy in Australia per RACGP/ARA guidelines.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander peoples experience a disproportionate burden of infectious and inflammatory diseases where TLR-mediated immunity plays a central role. Understanding these disparities is essential for culturally safe and clinically effective healthcare.

Infectious disease burden

Aboriginal and Torres Strait Islander Australians experience significantly higher rates of invasive pneumococcal disease (15× higher in children <5 years), rheumatic heart disease (Group A Streptococcus — TLR2/4-mediated recognition), and chronic hepatitis B (TLR7/9-mediated antiviral responses) compared with non-Indigenous Australians (AIHW, 2023). These infections are directly relevant to TLR-mediated innate immune defence.

Genetic considerations

Emerging research suggests unique TLR polymorphism distributions in Aboriginal and Torres Strait Islander populations, including TLR2 and TLR4 variants that may influence infection susceptibility and vaccine responses. Large-scale genomic studies (e.g., the Aboriginal and Torres Strait Islander Genomics Reference Panel) are underway to characterise these variants. Clinical immunodeficiency testing should be interpreted with reference population-specific data where available.

Rheumatic heart disease (RHD)

RHD remains a significant health disparity, with rates up to 80× higher in Aboriginal and Torres Strait Islander communities in northern Australia. TLR2-driven recognition of Group A Streptococcus (GAS) and subsequent autoimmune cross-reactivity with cardiac antigens (molecular mimicry) is central to RHD pathogenesis. Bicillin L-A (benzathine penicillin G) prophylaxis every 28 days remains the cornerstone of secondary prevention, delivered through Aboriginal Community Controlled Health Organisations (ACCHOs) and the RHD control programmes in NT, QLD, and WA.

Chronic hepatitis B

Chronic hepatitis B prevalence is 3–5× higher in Aboriginal and Torres Strait Islander populations, particularly in those born before universal infant vaccination (pre-2000). TLR7 and TLR9-mediated innate immune responses are critical for HBV containment; impaired responses contribute to chronicity. National hepatitis B vaccination programme catch-up and antiviral therapy (entecavir, tenofovir) access through ACCHOs are priorities.

Sepsis outcomes

Aboriginal and Torres Strait Islander Australians have higher sepsis incidence and mortality, driven by comorbid conditions (diabetes, chronic kidney disease, rheumatic heart disease) and delayed presentation due to geographical remoteness from tertiary healthcare. TLR4-mediated Gram-negative sepsis is particularly relevant in remote communities with higher rates of Gram-negative bacteraemia. Culturally safe rapid assessment and aeromedical retrieval are essential.

Vaccine access and efficacy

TLR-adjuvanted vaccines (AS01 in Shingrix®, AS04 in Cervarix®) rely on intact TLR4 function. Vaccine coverage rates remain lower in remote Aboriginal and Torres Strait Islander communities. The National Immunisation Programme provides free vaccination, but delivery challenges in remote areas require flexible outreach programmes through ACCHOs. Shingrix® is NIP-funded for immunocompromised individuals ≥18 years, including those with HIV — a population with higher prevalence in Aboriginal and Torres Strait Islander communities.

Cultural safety

Discussion of immune function and genetic testing should be undertaken with cultural sensitivity. Genomic research must comply with NHMRC ethical guidelines for research involving Aboriginal and Torres Strait Islander peoples (Values and Ethics framework, 2018) and be community-led with appropriate consent and data sovereignty provisions.

📚 References

1. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature Immunology. 2010;11(5):373–384.
2. O'Neill LAJ, Golenbock D, Bowie AG. The history of Toll-like receptors — redefining innate immunity. Nature Reviews Immunology. 2013;13(6):453–460.
3. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805–820.
4. Opal SM, Laterre PF, François B, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized controlled trial. JAMA. 2013;309(11):1154–1162.
5. Picard C, Casanova JL, Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency. Clinical Microbiology Reviews. 2011;24(3):490–497.
6. Zhang SY, Jouanguy E, Ugolini S, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science. 2007;317(5844):1522–1527.
7. Australian Institute of Health and Welfare (AIHW). Sepsis in Australia. Cat. no. PHE 317. Canberra: AIHW; 2023.
8. Australian Commission on Safety and Quality in Health Care (ACSQHC). Sepsis Clinical Care Standard. Sydney: ACSQHC; 2022.
9. National Health and Medical Research Council (NHMRC). Values and Ethics: Guidelines for Ethical Conduct in Aboriginal and Torres Strait Islander Health Research. Canberra: NHMRC; 2018.
10. Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annual Review of Immunology. 2011;29:447–491.
11. Bryant CE, Monie TP. Mice, men and the relatives: cross-species studies underpin innate immunity. Open Biology. 2012;2(4):120015.
12. Lancet Infectious Diseases Commission. Vaccine adjuvants: putting innate immunity to work. Lancet Infectious Diseases. 2020;20(10):e250–e261.
13. AIHW. Aboriginal and Torres Strait Islander Health Performance Framework 2020 summary report. Canberra: AIHW; 2020.
14. ANZDATA Registry. 45th Annual Report 2022 (Data to 2021). Adelaide: Australia and New Zealand Dialysis and Transplant Registry; 2022.
15. Rischmueller M, Tieu J, Lester S. Primary Sjögren's syndrome. Best Practice & Research Clinical Rheumatology. 2016;30(1):189–220.